menu
    • menu

    Company profile for Jiangsu Hengrui Medicine

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a global pharmaceutical company engaged in the development and commercialization of innovative and high-quality drugs, focusing on the research and development of new drugs in the fields of anti-tumor, surgical drugs, autoimmune diseases, metabolic diseases, and cardiovascular diseases. Innovation is the core development strategy. Hengrui has 12 innovative products and 1 cooperative...
    Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a global pharmaceutical company engaged in the development and commercialization of innovative and high-quality drugs, focusing on the research and development of new drugs in the fields of anti-tumor, surgical drugs, autoimmune diseases, metabolic diseases, and cardiovascular diseases. Innovation is the core development strategy. Hengrui has 12 innovative products and 1 cooperative innovative product marketed, more than 60 innovative candidates in the R&D stage, and more than 260 trials under clinical development around the world.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Jiangsu Hengrui MedicineChina Flag
    Country
    Country
    China
    Address
    Address
    No.7 Kunlunshan Road, Lianyungang Eco & Tech Development Zone, Lianyungang, Ji...
    Telephone
    Telephone
    +86 518 81220983
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.hengrui.com/en/about.html
    Linkedin
    Linkedin
    https://www.linkedin.com/company/jiangsu-hengrui-pharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI WW Frankfurt

    Not Confirmed

    envelop Contact Supplier

    CPhI WW Frankfurt

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    "50 Years of Innovation: Mikart

    mic"50 Years of Innovation: Mikart's legacy and what's next in CDMO excellence"

    This week, SpeakPharma interviews Michael Kallelis, CEO of Mikart, a leading contract development and manufacturing organization (CDMO) celebrating its 50th anniversary in the pharmaceutical industry. Based in the United States, Mikart has built a reputation for technical expertise, flexible business terms, and specialized capabilities in pharmaceutical development services. In this exclusive interview, Kallelis discusses how Mikart maintains its competitive edge through its Pharmaceutical Development Services team, quality control framework, and commitment to customized business solutions. Kallelis also explores the company's focus on liquid suspensions manufacturing, driven by growing demand from aging populations and pediatric patients, and explains how Mikart balances traditional family business values with modern innovation. HIGHLIGHTS// celebrating its 50th anniversary/ reputation for technical expertise/ how Mikart maintains its competitive edge Mikart is celebrating 50 years in business this year — what are some of the major milestones that have shaped the company's journey?  Over our 50-year history, we've celebrated many memorable milestones, but one of the most significant in recent years has been achieving our growth objectives. This success was driven by the strategic expansion of our Pharmaceutical Development Services team, the completion of full aggregate serialization in our packaging department, modernization of our IT systems, enhanced productivity, and our ability to attract both new and returning customers. HIGHLIGHTS// expansion of our Pharmaceutical Development Services team/ completion of full aggregate serialization/ attract both new and returning customers How has Mikart maintained its competitive edge in a constantly evolving pharmaceutical landscape? Our customers consistently tell us that what sets us apart is our technical expertise, high service level, and flexible, customized business terms. At the core of our competitiveness is our focus on Pharmaceutical Development Services (PDS). Mikart's PDS opinion leaders are actively engaged in business development and form early, collaborative relationships with our customers' technical teams. From the outset, our prospects and clients work directly with Mikart's experienced formulation chemists, analytical method developers, and process-oriented engineers to design robust, reproducible, and efficient processes. This hands-on development approach is supported by a comprehensive quality control testing framework — covering raw material testing, in-process checks, on-site microbiological testing, and in-house stability studies. Oversight is provided by our robust Quality Management System, managed by a dedicated Quality Assurance and Regulatory Affairs team. The result is disciplined problem-solving, timely FDA submissions, and a "right-first-time" philosophy that accelerates time-to-market. We operate with a strong sense of urgency and consistently deliver a high level of customer satisfaction. What truly differentiates Mikart is our commitment to customized business terms that eliminate common roadblocks seen with other CDMOs. Our secret sauce is our exceptional service and flexibility in helping our customers bring innovative medicines to patients. HIGHLIGHTS// technical expertise, high service level/ flexible, customized business terms/ comprehensive quality control testing framework/ dedicated Quality Assurance and Regulatory Affairs team/ timely FDA submissions/ accelerates time-to-market What capabilities or services does Mikart offer today that didn't exist 10 or 20 years ago? Mikart was an early leader in serialization, implementing full capabilities well ahead of the industry timeline. This proactive approach has kept our packaging team in high demand. We also upgraded our tablet compression equipment to enhance both speed and reliability. To support growing development needs, we invested in new lab-scale development equipment, unit dose cup filling, sachet packaging, low-humidity suites, and a brand-new suite dedicated to closed-system manufacturing of liquids and suspensions. Most recently, we launched a multi-million dollar expansion of our packaging lines to support higher-speed tablet filling, powder-in-bottle formats, and new liquid fill capabilities. HIGHLIGHTS// early leader in serialization/ upgraded our tablet compression equipment/ multi-million dollar expansion of our packaging lines Why are liquid suspensions becoming such a key focus, and how is Mikart positioned? Formulating suspensions is a complex process that requires specialized expertise and equipment. According to our customers, few mid-market CDMOs do it well — and Mikart is one of them. There is growing industry demand for high-quality suspension manufacturing, driven by the needs of the aging baby boomer population and pediatric patients. For both groups, swallowing tablets or capsules can be difficult, making oral liquid suspensions a more practical alternative. In addition to being easier to administer, suspensions offer pharmacological advantages and can improve dosing compliance. Enhanced flavoring techniques further improve the patient experience — especially for children and infants — by making medicines more palatable. HIGHLIGHTS// growing industry demand for high-quality suspension manufacturing/ suspensions offer pharmacological advantages/ improve dosing compliance How does Mikart balance tradition with innovation to meet modern customer demands?  At Mikart, we work hard to preserve the values of a traditional family business, even as we continue to modernize. Our goal is to make every customer feel like they are our top priority. Each customer is supported by a dedicated project manager who serves as their primary point of contact, along with direct access to key team members across departments. This structure ensures our customers are never isolated from our subject matter experts and can get timely, accurate answers to their questions. We're also mindful of the "technology trap" — the tendency to pursue every new innovation at the expense of focus and efficiency. Instead, we rely on market data and customer trends to guide our investments, enabling us to concentrate our resources and capital on technologies that meet real market needs. HIGHLIGHTS// customer is supported by a dedicated project manager/ customers are never isolated from our subject matter experts/ we rely on market data and customer trends to guide our investments/ meet real market needs Looking ahead, what's in store for Mikart in the next 5-10 years? Mikart's strategic plan is now in full motion, and with the momentum we've built, 50 percent growth is within reach. This projection is backed by a strong pipeline of annual FDA filings, a growing customer base, and a robust portfolio of active Pharmaceutical Development Services projects. As we grow, we remain committed to delivering exceptional service and continuously evolving to meet the changing needs of our customers. With renewed political emphasis on domestic manufacturing for the US market, we are ideally positioned to support the rapid, cost-effective development and production of high-quality medicines here at home. As we approach our 50th anniversary in the CDMO industry, we celebrate our legacy and look forward with optimism to the opportunities ahead in the next 5 to 10 years. HIGHLIGHTS// 50 percent growth is within reach/ strong pipeline of annual FDA filings 

    Impressions: 2853

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence

    PharmaCompass
    17 Jul 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaIngredients for Innovative FormulationsIngredients for Innovative Formulations

    Ingredients for Innovative Formulations
    Ingredients for Innovative Formulations

    reelIngredients for Innovative Formulations

    This PharmaReel highlights Kirsch Pharma’s expertise in providing premium quality raw materials, custom blends, and tailor-made solutions. With 40+ years of expertise and certified quality (GMP, ISO 9001, FSSC 22000, Halal, Kosher), Kirsch supports pharma, biotech, and nutrition industries worldwide.

    Impressions: 1289

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Global API micronization market set to surge 49% by 2030, led by specialized industry pioneers

    Global API micronization market set to surge 49% by 2030, led by specialized industry pioneers

    Precise particle size control has become the cornerstone of modern pharmaceutical manufacturing. With highly potent active pharmaceutical ingredients (HPAPIs) and complex formulations driving unprecedented demand, micronization technology is no longer optional — it's critical. The market reflects this urgency. The global API micronization market will jump from US$ 2.47 billion in 2024 to US$ 3.68 billion by 2030 — a 49 percent surge driven by a robust 6.84 percent CAGR. What's powering this growth? Strategic innovation by industry leaders. Companies like Munit SA, Lonza, Catalent, Veranova, EUROAPI, AGC Pharma Chemicals, Hovione and Coral Drugs aren't just participating — they're defining the future of pharmaceutical particle engineering. The Micronization Landscape: How leading companies are advancing pharmaceutical particle engineering The API micronization space is being shaped by companies with specialized expertise. Munit’s proprietary fluid jet milling technology brings particle sizes down to the 1-micron level — critical for inhalation therapies. In addition, this technology enables precise control over particle size distribution without mechanical impact, making it ideal for heat-sensitive and high-potency APIs. With decades of hands-on experience, Munit ensures batch-to-batch consistency, scalability from R&D to commercial volumes, and full compliance with GMP standards.  Munit offers high-containment isolators — including glove boxes for R&D and half-suit isolators for larger batches — with industry-leading containment levels, limiting airborne drug exposure to as low as 0.025 micrograms per cubic meter. This makes it particularly well-suited for handling highly potent or sensitive compounds, exceeding the capabilities of other commercial-scale players like Catalent, who typically achieve containment levels of 0.05 micrograms per cubic meter or higher. EUROAPI has taken a broad particle engineering approach, offering both micronization and spray drying across multiple dosage routes — oral, inhaled, and parenteral. AGC Pharma Chemical leverages spray drying and amorphous solid dispersion technologies across small molecules, peptides, ADCs, and oligonucleotides, exemplifying the evolving intersection of particle engineering and modern drug delivery innovation. Coral Drugs delivers cutting-edge technology and customization capabilities that tailor particle sizes to specific client requirements across tablets, injectables, and topicals. This dynamic competitive landscape continues to evolve as companies expand capabilities and form strategic partnerships. This year, Dec Group announced the launch of their cutting-edge Micronization Suite, now operational in Brick, New Jersey, while Lonza joined the Centre for Continuous Manufacturing and Advanced Crystallisation, an international research hub, to develop innovative continuous processing and crystallization solutions. Selecting the right micronization partner: Key success factors In a pharmaceutical landscape increasingly defined by complexity, precision, and speed-to-market, the choice of a micronization partner can significantly influence a drug’s success. Among the players in this space, Munit SA has emerged as a trusted and strategic ally for pharmaceutical companies worldwide. But what exactly sets Munit apart in the micronization market? To begin with, Munit SA brings over 60 years of experience in particle size engineering. This legacy is not just a number; it reflects decades of accumulated knowledge, process refinement, and a deep understanding of how particle size impacts drug performance. In an industry where even minor deviations can compromise efficacy or safety, this level of experience is invaluable. It has delivered over 500 successful micronization projects to more than 150 customers globally. At its core, Munit SA is laser-focused on micronization and milling — not as ancillary services, but as its primary mission. Their facilities are designed for processing high-potency APIs, cytotoxic and cytostatic compounds, non-beta-lactam antibiotics, steroids, and controlled substances under stringent containment protocols. The company also handles inhalation products, peptides, biological drugs, generics, and R&D compounds. Whether it's micronization for ophthalmic formulations, transdermal or oral products, Munit offers a tailored approach. It stands as a world-leading provider of micronization services in inhalation powders with particle sizes of 1-5 microns and specialized oncology applications for small molecules. In an increasingly complex global landscape, Munit SA addresses supply chain challenges through its dual-site operational model, with facilities in Switzerland (Jetpharma SA) and Italy (Microchem S.r.l). This strategic setup mitigates risks from regulatory changes, geopolitical tensions, or environmental disruptions, ensuring continuous production and delivery of critical APIs. This resilience makes Munit a trusted partner for companies prioritizing business continuity. Why pharmaceutical companies choose Munit for advanced micronization and milling Munit’s proprietary MC Jet Mill is a testament to its engineering excellence. For heat-sensitive APIs, Munit’s cryogenic micronization process uses liquid nitrogen to cool materials, preventing thermal degradation and preserving the integrity of delicate molecules. This is particularly valuable for biologics and APIs with low melting points, where stability is paramount. Additionally, Munit’s under containment micronization employs advanced systems to safely handle HPAPIs, protecting both operators and the environment while meeting stringent regulatory standards.  Their co-micronization service, which processes APIs alongside excipients, further enhances formulation stability and solubility, offering innovative solutions for complex drug profiles. These capabilities, executed under Good Manufacturing Practices (GMP), make Munit a reliable choice for pharmaceutical companies seeking precision and quality. While micronization is Munit’s flagship, it offers milling services through an array of technologies, each suited to specific needs. The Pin Mill uses a grinding chamber and particle size reduction is achieved due impact against a high-speed pin rotor, producing sizes from 50 to 150 microns. It’s particularly effective for APIs needing improved flow for tableting, offering precise size control that ensures uniformity. The Quadro Co-Mill excels at soft de-lumping and homogenization, using a conical sieve and impeller to gently process powders without altering primary particle sizes. For tougher materials, the HammerMill C-10 employs hammer bars on a rotor to crush particles. State-of-the-Art Particle Engineering: Munit's strategic innovation push delivers next-gen solutions Munit’s leadership in micronization is underpinned by a deliberate and sustained investment in innovation — aimed at building the next generation of particle size engineering. In response to client challenges with condensation and product degradation, Munit developed a proprietary conditioning system that precisely controls humidity and temperature. Engineered with ergonomic design and fluid dynamics principles, their machine represents a qualitative leap in conditioning. Munit's new AIFA-approved Building C transforms the Italian hub's capacity. Equipped for high potent, toxic, cytotoxic, and cytostatic compounds, alongside hormones, it features cutting-edge safety systems and integrated technologies, enabling broader API processing with precision and compliance. Munit has merged quality assurance and regulatory affairs into one strategic unit, streamlining workflows and enhancing client responsiveness during critical validation phases. This delivers tailored regulatory support and accelerates time-to-market. These initiatives position Munit at the forefront of particle size engineering, where state-of-the-art innovation, regulatory excellence, and client-centric design converge to set new industry standards. Our view The API micronization market is projected to grow 49 percent to US$ 3.68 billion by 2030. In this evolving landscape, companies that combine deep technical expertise with operational resilience are positioned to capture the greatest value. Munit SA exemplifies this winning formula.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2758

    https://www.pharmacompass.com/radio-compass-blog/global-api-micronization-market-set-to-surge-49-by-2030-led-by-specialized-industry-pioneers

    #Phispers by PHARMACOMPASS
    10 Sep 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Hengrui Licenses Heart Disease Drug to US Startup for up to $1B+
    Hengrui Licenses Heart Disease Drug to US Startup for up to $1B+

    06 Sep 2025

    // BIOSPACE

    https://www.biospace.com/business/hengrui-licenses-heart-disease-drug-to-us-startup-for-up-to-1b

    BIOSPACE
    06 Sep 2025
    Share Share
    Hengrui’s GLP-1/GIP Agonist Reports 18% Weight Loss in Phase 3
    Hengrui’s GLP-1/GIP Agonist Reports 18% Weight Loss in Phase 3

    16 Jul 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/hengruis-glp-1gip-agonist-reports-18-weight-loss-phase-3-trial-readies-china-push

    FIERCE BIOTECH
    16 Jul 2025
    Share Share
    Hengrui’s Heng Qin Gets Nod For Dry Eye Linked To MGD
    Hengrui’s Heng Qin Gets Nod For Dry Eye Linked To MGD

    08 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250708514269/en/Breakthrough-in-Ophthalmology-Hengruis-Heng-Qin-Perfluorohexyloctane-Eye-Drops-Approved-as-First-Treatment-for-Dry-Eye-Disease-Associated-with-MGD

    BUSINESSWIRE
    08 Jul 2025
    Share Share
    Jiangsu Hengrui and Kailera present data at ADA 85th Sessions
    Jiangsu Hengrui and Kailera present data at ADA 85th Sessions

    16 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/16/3099707/0/en/Jiangsu-Hengrui-Pharmaceuticals-and-Kailera-Therapeutics-Announce-Clinical-Data-Presentations-at-the-American-Diabetes-Association-85th-Scientific-Sessions.html

    GLOBENEWSWIRE
    16 Jun 2025
    Share Share
    IDEAYA Biosciences Announces FDA IND-Clearance for IDE849
    IDEAYA Biosciences Announces FDA IND-Clearance for IDE849

    06 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-us-fda-ind-clearance-for-ide849-a-potential-first-in-class-dll3-top1-adc-for-a-phase-1-study-in-solid-tumors-302446498.html

    PR NEWSWIRE
    06 May 2025
    Share Share
    Mycovia Pharma partners with Jiangsu Hengrui Pharma for Vivjoa
    Mycovia Pharma partners with Jiangsu Hengrui Pharma for Vivjoa

    02 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mycovia-pharmaceuticals-inc-announces-partner-jiangsu-hengrui-pharmaceuticals-co-ltds-recognition-for-the-inclusion-of-vivjoa-oteseconazole-capsules-in-the-chinese-national-reimbursement-drug-list-302417640.html

    PR NEWSWIRE
    02 Apr 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Phase I Study of HRS-7172 in Advanced Solid Tumors with RAS Mutations/Amplifications

    Details:

    HRS-7172 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.


    Lead Product(s): HRS-7172,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Other Small Molecule

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 27, 2025

    blank

    01

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : HRS-7172,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Phase I Study of HRS-7172 in Advanced Solid Tumors with RAS Mutations/Amplifications

    Details : HRS-7172 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    August 27, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    HRS-9190 IV Bolus/Infusion Safety, PK/PD In Healthy Adults

    Details:

    HRS-9190 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.


    Lead Product(s): HRS-9190,Inapplicable

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Undisclosed

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 27, 2025

    blank

    02

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : HRS-9190,Inapplicable

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    HRS-9190 IV Bolus/Infusion Safety, PK/PD In Healthy Adults

    Details : HRS-9190 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    August 27, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study of HRS-4508 in Combination with Other Anti-tumor Therapy for Solid Tumor

    Details:

    HRS-4508 is a drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.


    Lead Product(s): HRS-4508,Capecitabine,Trastuzumab,Pertuzumab,A1811

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Undisclosed

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 24, 2025

    blank

    03

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : HRS-4508,Capecitabine,Trastuzumab,Pertuzumab,A1811

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study of HRS-4508 in Combination with Other Anti-tumor Therapy for Solid Tumor

    Details : HRS-4508 is a drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    August 24, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Phase I/II Clinical Study of FH-006 for Injection in Patients with Solid Tumors

    Details:

    FH-006 is a drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.


    Lead Product(s): FH-006,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Undisclosed

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 22, 2025

    blank

    04

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : FH-006,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Phase I/II Clinical Study of FH-006 for Injection in Patients with Solid Tumors

    Details : FH-006 is a drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    August 22, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Phase I Study of HRS-6093 in KRAS G12D Advanced Solid Tumors

    Details:

    HRS-6093 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.


    Lead Product(s): HRS-6093,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Other Small Molecule

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 21, 2025

    blank

    05

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : HRS-6093,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Phase I Study of HRS-6093 in KRAS G12D Advanced Solid Tumors

    Details : HRS-6093 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    August 21, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    HRS-4642 + Chemo + Adebrelimab Safety and Efficacy In Pancreatic Cancer

    Details:

    HRS-4642 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Pancreatic Neoplasms.


    Lead Product(s): HRS-4642,Gemcitabine,Paclitaxel,Adebrelimab

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Undisclosed

    Recipient: Ruijin Hospital

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 20, 2025

    blank

    06

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : HRS-4642,Gemcitabine,Paclitaxel,Adebrelimab

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Recipient : Ruijin Hospital

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    HRS-4642 + Chemo + Adebrelimab Safety and Efficacy In Pancreatic Cancer

    Details : HRS-4642 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Pancreatic Neoplasms.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    August 20, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RSS0393 Topical Ointment Safety and PK In Children/Adolescents with Plaque Psoriasis

    Details:

    RSS0393 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Psoriasis.


    Lead Product(s): RSS0393,Inapplicable

    Therapeutic Area: Dermatology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Undisclosed

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 05, 2025

    blank

    07

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : RSS0393,Inapplicable

    Therapeutic Area : Dermatology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    RSS0393 Topical Ointment Safety and PK In Children/Adolescents with Plaque Psoriasis

    Details : RSS0393 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Psoriasis.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    August 05, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    SHR2554 + Antitumor Therapies In Gastric Or GEJ Adenocarcinoma

    Details:

    SHR2554 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Stomach Neoplasms.


    Lead Product(s): SHR2554,SHR-A1811,SHR-A1904,SHR-1701

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Other Small Molecule

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 05, 2025

    blank

    08

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : SHR2554,SHR-A1811,SHR-A1904,SHR-1701

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    SHR2554 + Antitumor Therapies In Gastric Or GEJ Adenocarcinoma

    Details : SHR2554 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Stomach Neoplasms.

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    August 05, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Hetrombopag to Prevent Thrombocytopenia From Lung Cancer Therapy

    Details:

    Hetrombopag is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Lung Neoplasms.


    Lead Product(s): Hetrombopag,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Other Small Molecule

    Recipient: Shanghai Pulmonary Hospital

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 03, 2025

    blank

    09

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Hetrombopag,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Recipient : Shanghai Pulmonary Hospital

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Hetrombopag to Prevent Thrombocytopenia From Lung Cancer Therapy

    Details : Hetrombopag is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Lung Neoplasms.

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    August 03, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    RSS0343 Tablets Safety, PK/PD, and Food Effect in Single & Multiple Oral Doses

    Details:

    RSS0343 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.


    Lead Product(s): RSS0343,Inapplicable

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Undisclosed

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 03, 2025

    blank

    10

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed

    Jiangsu Hengrui Medicine

    China
    arrow
    Biotech Week Boston
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : RSS0343,Inapplicable

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    RSS0343 Tablets Safety, PK/PD, and Food Effect in Single & Multiple Oral Doses

    Details : RSS0343 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    August 03, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    Brand Name : N/A

    China
    Boulder Peptide
    Not Confirmed
    arrow

    Brand Name : N/A

    China
    arrow
    Boulder Peptide
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : China

    Abiraterone Acetate

    Jiangsu Hengrui Medicine

    Dosage Form : Tablet

    Brand Name :

    Dosage Strength : 250MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : China

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : N/A

    China
    Boulder Peptide
    Not Confirmed
    arrow

    Brand Name : N/A

    China
    arrow
    Boulder Peptide
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : China

    Acetylsalicylic Acid; Dipyridamole

    Jiangsu Hengrui Medicine

    Dosage Form : SR Capsule

    Brand Name :

    Dosage Strength : 25MG; 200MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : China

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : N/A

    China
    Boulder Peptide
    Not Confirmed
    arrow

    Brand Name : N/A

    China
    arrow
    Boulder Peptide
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : China

    Ambroxol Hydrochloride

    Jiangsu Hengrui Medicine

    Dosage Form : Oral Solution

    Brand Name :

    Dosage Strength : 300MG/100ML

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : China

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : N/A

    China
    Boulder Peptide
    Not Confirmed
    arrow

    Brand Name : N/A

    China
    arrow
    Boulder Peptide
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : China

    Ambroxol Hydrochloride

    Jiangsu Hengrui Medicine

    Dosage Form : Tablet

    Brand Name :

    Dosage Strength : 30MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : China

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : N/A

    China
    Boulder Peptide
    Not Confirmed
    arrow

    Brand Name : N/A

    China
    arrow
    Boulder Peptide
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : China

    Ambroxol Hydrochloride

    Jiangsu Hengrui Medicine

    Dosage Form : Oral Solution

    Brand Name :

    Dosage Strength : 600MG/100ML

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : China

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : N/A

    China
    Boulder Peptide
    Not Confirmed
    arrow

    Brand Name : N/A

    China
    arrow
    Boulder Peptide
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : China

    Atracurium Besylate

    Jiangsu Hengrui Medicine

    Dosage Form : Injection

    Brand Name :

    Dosage Strength : 25MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : China

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : N/A

    China
    Boulder Peptide
    Not Confirmed
    arrow

    Brand Name : N/A

    China
    arrow
    Boulder Peptide
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : China

    Atracurium Besylate

    Jiangsu Hengrui Medicine

    Dosage Form : Injection

    Brand Name :

    Dosage Strength : 10MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : China

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Brand Name : N/A

    China
    Boulder Peptide
    Not Confirmed
    arrow

    Brand Name : N/A

    China
    arrow
    Boulder Peptide
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : China

    azelastine hydrochloride

    Jiangsu Hengrui Medicine

    Dosage Form : Nasal Spray

    Brand Name :

    Dosage Strength : 10MG/10ML

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : China

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Brand Name : N/A

    China
    Boulder Peptide
    Not Confirmed
    arrow

    Brand Name : N/A

    China
    arrow
    Boulder Peptide
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : China

    Bimatoprost

    Jiangsu Hengrui Medicine

    Dosage Form : Ophthalmic Solution

    Brand Name :

    Dosage Strength : 0.9MG/3ML

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : China

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Brand Name : N/A

    China
    Boulder Peptide
    Not Confirmed
    arrow

    Brand Name : N/A

    China
    arrow
    Boulder Peptide
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : China

    Bimatoprost

    Jiangsu Hengrui Medicine

    Dosage Form : Ophthalmic Solution

    Brand Name :

    Dosage Strength : 1.5MG/5ML

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : China

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact JIANGSU HENGRUI MEDICINE CO. LTD and get a quotation

    JIANGSU HENGRUI MEDICINE CO. LTD is a supplier offers 38 products (APIs, Excipients or Intermediates).

    Find a price of Oxaliplatin bulk with DMF, CEP, JDMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Letrozole bulk with CEP, JDMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Sevoflurane bulk with CEP, JDMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Dexmedetomidine Hydrochloride bulk with DMF, JDMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Etoposide bulk with DMF, CEP offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Irinotecan Hydrochloride bulk with DMF, JDMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Ifosfamide bulk with DMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Apatinib bulk with DMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Bupivacaine bulk with DMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Carmustine bulk with DMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Caspofungin bulk with DMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Cisatracurium Besylate bulk with DMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Cyclophosphamide bulk with DMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Desflurane bulk with DMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Docetaxel bulk with DMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Fondaparinux Sodium bulk with DMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Gadobutrol bulk with DMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Gadoterate Meglumine bulk with DMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Iodixanol bulk with DMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Ivarmacitinib bulk with DMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Oxaliplatin bulk with CEP offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Sevoflurane bulk with DMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Tolvaptan bulk with DMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of SHR169106 bulk with DMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of ER301 NON-STERILE DRUG SUBSTANCE INTERMEDIATE bulk with DMF offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Letrozole, Process II bulk with CEP offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Azelastine Hydrochloride bulk offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Capecitabine bulk offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Gabapentin bulk offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Ioversol bulk offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Ivabradine Hydrochloride bulk offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Mesna bulk offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Tamsulosin bulk offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Thiotepa bulk offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Trabectedin bulk offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Dexmedetomidine Hydrochloride bulk offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Iodixanol bulk offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Find a price of Letrozole bulk offered by JIANGSU HENGRUI MEDICINE CO. LTD

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search